Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 19;17(12):sfae336.
doi: 10.1093/ckj/sfae336. eCollection 2024 Dec.

Associations between plasma osteopontin, sex, and 2-year global and cardiorenal outcomes in older outpatients screened for CKD: a secondary analysis of the SCOPE study

Luca Soraci  1 , Johan Ärnlöv  2   3 , Axel C Carlsson  3   4 , Tobias Rudholm Feldreich  2   3 , Anders Larsson  5 , Regina Roller-Wirnsberger  6 , Gerhard Wirnsberger  6 , Francesco Mattace-Raso  7 , Lisanne Tap  7 , Francesc Formiga  8 , Rafael Moreno-González  8 , Bartlomiej Soltysik  9 , Joanna Kostka  10 , Rada Artzi-Medvedik  11   12 , Itshak Melzer  11 , Christian Weingart  13 , Cornel Sieber  13   14 , Serena Marcozzi  1 , Lucia Muglia  1 , Fabrizia Lattanzio  1 ; Screening for CKD among Older People across Europe (SCOPE) study investigators
Collaborators, Affiliations

Associations between plasma osteopontin, sex, and 2-year global and cardiorenal outcomes in older outpatients screened for CKD: a secondary analysis of the SCOPE study

Luca Soraci et al. Clin Kidney J. .

Abstract

Background: Plasma osteopontin (pOPN) is a promising aging-related biomarker among individuals with and without kidney disease. The interaction between sex, pOPN levels, and global and cardiorenal outcomes among older individuals was not previously evaluated.

Methods: In this study we investigated the association of pOPN with 24-month global mortality, major cardiovascular events (MACEs), MACEs + cardiovascular (CV) mortality, and renal decline among older individuals; we also evaluated whether sex modified observed associations. pOPN levels were measured in a cohort of 2013 outpatients (908 men and 1105 women) aged 75 years or more enrolled in the context of a multicenter prospective cohort study in Europe. Multivariable linear regression, Cox and Fine Gray models, and linear mixed regression models were fitted to evaluate whether sex modified the associations between biomarkers and study outcomes.

Results: In total, 2013 older participants with a median age of 79 years, 54.9% of whom women, were included in the study; increased pOPN levels were associated with all-cause mortality specifically among women [reduced fully adjusted model resulting from backward selection, hazard ratio, 95% confidence interval (CI): 1.84, 1.20-2.89]. Addition of pOPN to models containing age, eGFR, and albumin-to-creatinine ratio (ACR) improved the time-dependent area under the curve (AUC) at 6, 12, and 24 months, among women only. No significant association was found between the biomarker levels, MACE, and MACE + CV mortality. Conversely, increased baseline pOPN was associated with eGFR decline in all patients (-0.45, 95%CI: -0.68 to -0.22 ml/min/1.73 m2 year) but with slightly steeper declines in women compared to men (-0.57, -0.99 to -0.15 vs -0.47, -0.88 to -0.07).

Conclusions: pOPN levels were significantly lower in women than in men but associated with all-cause mortality in women only; increase in serum pOPN was associated with eGFR decline over time in all patients, but with stronger associations among women. Assessment of pOPN may help identifying older female participants at risk of poor outcomes.

Keywords: biomarkers; chronic kidney disease; older patients; osteopontin; renal decline.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest. The funding body had no role in the design of the study and collection, analysis, and interpretation of data, writing the manuscript and in the decision to publish the results.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Correlations between pOPN, eGFR, ACR, PTH, calcium, phosphate, and vitamin D, in the overall study population and in men and women separately.
See this image and copyright information in PMC

References

    1. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018;59:17–24. 10.1016/j.clinbiochem.2018.07.003 - DOI - PubMed
    1. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615–22. 10.1016/S0945-053X(00)00108-6 - DOI - PubMed
    1. Shirakawa K, Sano M. Osteopontin in cardiovascular diseases. Biomolecules 2021;11:1047. 10.3390/biom11071047 - DOI - PMC - PubMed
    1. Paloian NJ, Leaf EM, Giachelli CM. Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification. Kidney Int 2016;89:1027–36. 10.1016/j.kint.2015.12.046 - DOI - PMC - PubMed
    1. Stubbs JR, Zhang S, Jansson KP et al. Critical role of osteopontin in maintaining urinary phosphate solubility in CKD Kidney360 2022;3:1578–89. 10.34067/KID.0007352021 - DOI - PMC - PubMed